# S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer

> **NCT00103324** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Diffuse Adenocarcinoma of the Stomach
- Intestinal Adenocarcinoma of the Stomach
- Mixed Adenocarcinoma of the Stomach
- Recurrent Gastric Cancer
- Stage III Gastric Cancer
- Stage IV Gastric Cancer

## Interventions

- **DRUG:** lapatinib ditosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00103324
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103324, "S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00103324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*